IBM Watson Health and Teva Pharmaceuticals Industries Inc announced that Teva has been selected as its
first Foundational Life Sciences Partner for the Watson Health Cloud. As
part of this new strategic partnership, Teva becomes the first global
pharmaceutical company to tap the power of the Watson Health Cloud to
benefit patients and healthcare providers across geographies.
Teva has chosen the IBM Watson Health Cloud as a preferred global
technology platform and aims to build solutions designed to help
millions of individuals worldwide with complex and chronic conditions
such as asthma, pain, migraine and neurodegenerative diseases. In
addition, a joint Teva-IBM Research team will deploy Big Data and
machine learning technology to create disease models and advanced
therapeutic solutions.
Watson is a groundbreaking cognitive computing platform that represents
a new era of computing based on its ability to interact in natural
language, process vast amounts of Big Data to uncover patterns and
insights, and learn from each interaction. The Watson Health Cloud
provides an open development platform for physicians, researchers,
insurers and companies focused on creating health and wellness solutions.
Teva will work with IBM on long-range platform and solutions
development, with experts collaborating to enhance IBM Watson Health
Cloud capabilities and explore synergies with existing Watson Health
ecosystem partners. The company, which has one of the world’s largest
portfolios of medicines, expects to develop solutions designed to
collect and analyze real world evidence, draw powerful insights and
inform a variety of initiatives such as reducing drug misuse or
increasing prescribed medication adherence.
